Loading…
Loading…
Disc Medicine (IRON) is experiencing a significant surge today following the announcement of positive results from its pivotal Phase 3 APOLLO trial for bitopert
Positive APOLLO trial topline results demonstrated statistically significant and clinically meaningful benefit across all study endpoints Successfully met co-primary endpoints of reduction in protoporphyrin IX (PPIX) and increased total time in light All secondary endpoint results were also positive and statistically significant, including reductions in phototoxic reactions and improvements on multiple measures of light tolerance Exploratory endpoints of quality-of-life improvement were also statistically significant Bitopertin was generally well-tolerated with no new safety signals observed in APOLLO Disc plans to resubmit an NDA to FDA by end of 2026, with an FDA decision anticipated by mid-2027 Disc to discuss topline results in a corporate webcast on October 19, 2026 at 8:00am ET WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced topline results from the APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyria (EPP), including X-linked protoporphyria (XLP).
WATERTOWN, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it will host a corporate webcast to discuss topline results from the APOLLO Phase 3 trial of bitopertin in EPP. The webcast will be held on Monday, October 19, 2026 at 8:00 a.m. ET.
iShares MSCI Pacific ex Japan ETF (NYSEARCA:EPP - Get Free Report) was the recipient of a large increase in short interest in the month of September. As of September 15th, there was short interest totaling 46,767 shares, an increase of 92.9% from the August 31st total of 24,243 shares. Approximately 0.1% of the company's shares
The yen's surge may be signaling something much bigger than another carry-trade scare: the price of Japanese capital is changing. For the first time in decades, rising JGB yields are making it increasingly rational for Japanese investors to keep more money at home.
Japan's consumer inflation picked up last month as the effects of higher oil prices caused by the Middle East conflict broadened.
Health Canada NOC enables treatment for porphyria, metabolic disorder Health Canada NOC enables treatment for porphyria, metabolic disorder
PALO ALTO, Calif.--(BUSINESS WIRE)--GondolaBio, a clinical-stage biopharmaceutical company developing novel medicines for patients living with genetic diseases, on behalf of its affiliate Portal Therapeutics, today announced positive data from its Phase 2a GATEWAY trial of PORT-77 in patients with erythropoietic protoporphyria (EPP). PORT-77 is a novel investigational oral, small molecule ABCG2 inhibitor designed to treat EPP and X-linked protoporphyria (XLP), two rare genetic disorders charact.